Trial · NCT07908732
Risk-Adapted Segmental Esophagus-Sparing Radiotherapy for Definitive Non-Small Cell Lung Cancer
NCT07908732, Phase 3, Not yet recruiting, Ruijin Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Risk-Adapted Segmental Esophagus-Sparing Radiotherapy for Definitive Non-Small Cell Lung Cancer. Trials, record NCT07908732. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908732
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Risk-Adapted Segmental Esophagus-Sparing Radiotherapy for Definitive Non-Small Cell Lung Cancer
- NCT number
- NCT07908732
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 140 participants, estimated
- Lead sponsor
- Ruijin Hospital
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Risk-Adapted Segmental Esophagus-Sparing IMRT/VMAT, Standard IMRT/VMAT Without Active Esophageal Avoidance
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Grade 2 or Higher Acute Radiation Esophagitis (CTCAE v5.0) | From start of radiotherapy to 3 months after completion of radiotherapy (approximately 4.5-5 months after radiotherapy initiation) | Proportion of participants who develop Grade 2 or higher acute radiation esophagitis, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, from the start of radiotherapy until 3 months after the end of radiotherapy. The primary analysis will use the intention-to-treat population. The primary endpoint will be assessed by investigators; the statistical analysis will be performed by an independent statistician blinded to treatment allocation. |
| Secondary | Incidence of Any-Grade Acute Radiation Esophagitis | From start of radiotherapy to 3 months after completion of radiotherapy. | Proportion of participants who develop any-grade acute radiation esophagitis, assessed by both CTCAE v5.0 and RTOG criteria. Events occurring from the start of radiotherapy until 3 months after completion of radiotherapy will be recorded. |
| Secondary | Incidence of Grade 3 or Higher Acute Radiation Esophagitis | From start of radiotherapy to 3 months after completion of radiotherapy. | Proportion of participants who develop Grade 3 or higher acute radiation esophagitis, graded according to CTCAE v5.0, from the start of radiotherapy until 3 months after completion of radiotherapy. |
| Secondary | Incidence of Other Acute Radiation-Related Toxicities | From start of radiotherapy to 3 months after completion of radiotherapy. | Proportion of participants who develop other acute radiation-related toxicities, including pulmonary, cardiac, hepatic, spinal cord, and skin toxicity, graded according to CTCAE v5.0, from the start of radiotherapy until 3 months after completion of radiotherapy. |
| Secondary | Incidence of Late Esophageal Toxicity | From 3 months after completion of radiotherapy through 24 months after randomization. | Proportion of participants who develop late esophageal radiation-related toxicity after completion of radiotherapy, assessed according to RTOG late toxicity criteria. |
| Secondary | Progression-Free Survival at 1 and 2 Years | From start of study treatment; assessed at 1 and 2 years. | Progression-free survival is defined as the time from the start of study treatment (chemoradiotherapy) to tumor recurrence/progression or last follow-up. PFS rates at 1 and 2 years will be estimated using Kaplan-Meier methods. |
| Secondary | Overall Survival | From start of study treatment through up to 24 months after randomization. | Overall survival is defined as the time from the start of study treatment (chemoradiotherapy) to death from any cause or last follow-up. Survival status will be collected through the long-term follow-up period. |
| Secondary | Locoregional Progression-Free Survival | From start of study treatment through up to 24 months after randomization. | Locoregional progression-free survival is defined as the time from the start of study treatment to locoregional progression/recurrence or death from any cause, whichever occurs first, or last follow-up. |
| Secondary | Objective Response Rate | From start of study treatment until disease progression/recurrence or last tumor assessment; assessed up to 24 months after randomization. | Objective response rate is defined as the proportion of participants with a best overall response of complete response or partial response, assessed by imaging (CT/MRI/PET-CT) according to RECIST 1.1. |
| Secondary | In-Field and Marginal Recurrence Rates at 1 and 2 Years | From start of study treatment; assessed at 1 and 2 years. | In-field recurrence is defined as tumor recurrence within the original irradiated target volume. Marginal recurrence is defined as recurrence within 1 cm outside the planning target volume (PTV) in any direction. Recurrence will be assessed by imaging and pathology when available. Cumulative rates at 1 and 2 years will be estimated. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07908732
GET https://conductscience.org/api/trials/v1/NCT07908732/registered